Candice Jamois
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial.
Journal: Nature medicine
Published: December 15, 2025
Enhancing Severe Neutropenia Prediction: PKPD-Informed Labeling for Machine Learning Models Trained on Real-World Data.
Journal: Clinical pharmacology and therapeutics
Published: July 30, 2025
Building Hybrid Pharmacometric-Machine Learning Models in Oncology Drug Development: Current State and Recommendations.
Journal: CPT: pharmacometrics & systems pharmacology
Published: July 11, 2025
Guideline-based strategies to identify severe cytokine release syndrome in COVID-19 and cancer immunotherapy using large-scale electronic health records.
Journal: Frontiers in digital health
Published: May 09, 2025
Tocilizumab Dosing for Management of T Cell-Engaging Bispecific Antibody-Related CRS in Patients With R/R B-Cell NHL.
Journal: Clinical pharmacology and therapeutics
Published: January 15, 2025
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes.
Journal: Clinical pharmacology and therapeutics
Published: January 05, 2025
Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre- and on-Treatment Prognostic Biomarkers.
Journal: Clinical pharmacology and therapeutics
Published: March 14, 2024
Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T‑Cell Bispecific in Combination with Anti‑PD‑L1.
Journal: The AAPS journal
Published: March 31, 2023
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.
Journal: Nature communications
Published: January 30, 2023
Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1.
Journal: The AAPS journal
Published: June 23, 2022
Rituximab pediatric drug development: Pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis.
Journal: Clinical and translational science
Published: May 17, 2022
Last Updated: 09/26/2026